MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Search

Celldex Therapeutics Inc

Closed

SectorHealthcare

31.35 1.13

Overview

Share price change

24h

Current

Min

30.78

Max

32.01

Key metrics

By Trading Economics

Income

-14M

-81M

Sales

75K

75K

EPS

-1.22

Profit margin

-108,422.667

Employees

198

EBITDA

-7.8M

-81M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+73.57% upside

Dividends

By Dow Jones

Next Earnings

6 May 2026

Market Stats

By TradingEconomics

Market Cap

346M

2B

Previous open

30.22

Previous close

31.35

News Sentiment

By Acuity

100%

0%

333 / 349 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Celldex Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

6 Apr 2026, 23:17 UTC

Earnings

Samsung Forecasts Record First-Quarter Operating Profit

6 Apr 2026, 23:00 UTC

Hot Stocks

Stocks to Watch: Health Insurers, Mawson, Owlet

6 Apr 2026, 22:13 UTC

Major Market Movers

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 Apr 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 Apr 2026, 17:09 UTC

Major Market Movers

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 Apr 2026, 16:56 UTC

Major News Events

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 Apr 2026, 14:47 UTC

Major Market Movers

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 Apr 2026, 00:00 UTC

Major News Events

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 Apr 2026, 23:58 UTC

Market Talk
Major News Events

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 Apr 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 Apr 2026, 23:36 UTC

Market Talk

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 Apr 2026, 23:15 UTC

Market Talk

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 Apr 2026, 22:52 UTC

Market Talk

Global Equities Roundup: Market Talk

6 Apr 2026, 22:52 UTC

Market Talk

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 Apr 2026, 22:14 UTC

Market Talk

Correction to Live Cattle Futures Article

6 Apr 2026, 20:56 UTC

Market Talk

Mexican Private Consumption Fell in January -- Market Talk

6 Apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

6 Apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 Apr 2026, 19:58 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 Apr 2026, 19:58 UTC

Market Talk

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 Apr 2026, 19:11 UTC

Market Talk

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 Apr 2026, 19:06 UTC

Market Talk

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 Apr 2026, 19:03 UTC

Market Talk

Global Energy Roundup: Market Talk

6 Apr 2026, 19:03 UTC

Market Talk

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 Apr 2026, 18:36 UTC

Acquisitions, Mergers, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 Apr 2026, 17:59 UTC

Market Talk
Major News Events

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 Apr 2026, 17:13 UTC

Acquisitions, Mergers, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 Apr 2026, 16:33 UTC

Market Talk

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 Apr 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 Apr 2026, 14:59 UTC

Earnings

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Peer Comparison

Price change

Celldex Therapeutics Inc Forecast

Price Target

By TipRanks

73.57% upside

12 Months Forecast

Average 53.91 USD  73.57%

High 90 USD

Low 24 USD

Based on 12 Wall Street analysts offering 12 month price targets forCelldex Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

10

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

18.91 / 20.63Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat